Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Malkowicz

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Urology|March 29, 2000
Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimenD J Vaughn, S B Malkowicz, B Zoltick, et al.
DNA and Cell Biology|November 22, 2002
KIAA1096, a gene on chromosome 1q, is amplified and overexpressed in bladder cancerWilliam C Huang, Sherry Taylor, Trang B Nguyen, et al.
Urology|May 9, 2003
Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese menS M Gueye, C M Zeigler-Johnson, T Friebel, et al.
International Journal of Radiation Oncology, Biology, Physics|December 29, 1999
Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stageA V D'Amico, R Whittington, S B Malkowicz, et al.
Cancer|January 28, 1998
Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliterA V D'Amico, R Whittington, I Kaplan, et al.
The Journal of Urology|November 16, 2007
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical studyM R Smith, S B Malkowicz, F Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 1997
Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTVA V D'Amico, R Whittington, I Kaplan, et al.
The Journal of Urology|November 20, 1997
Collagen injection therapy for post-radical retropubic prostatectomy incontinence: role of Valsalva leak point pressureR F Sánchez-Ortiz, G A Broderick, D C Chaikin, et al.
Urology|December 23, 2008
Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?M J Resnick, D J Canter, T J Guzzo, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Urology|March 29, 2000
Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimenD J Vaughn, S B Malkowicz, B Zoltick, et al.
DNA and Cell Biology|November 22, 2002
KIAA1096, a gene on chromosome 1q, is amplified and overexpressed in bladder cancerWilliam C Huang, Sherry Taylor, Trang B Nguyen, et al.
Urology|May 9, 2003
Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese menS M Gueye, C M Zeigler-Johnson, T Friebel, et al.
International Journal of Radiation Oncology, Biology, Physics|December 29, 1999
Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stageA V D'Amico, R Whittington, S B Malkowicz, et al.
Cancer|January 28, 1998
Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliterA V D'Amico, R Whittington, I Kaplan, et al.
The Journal of Urology|November 16, 2007
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical studyM R Smith, S B Malkowicz, F Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 1997
Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTVA V D'Amico, R Whittington, I Kaplan, et al.
The Journal of Urology|November 20, 1997
Collagen injection therapy for post-radical retropubic prostatectomy incontinence: role of Valsalva leak point pressureR F Sánchez-Ortiz, G A Broderick, D C Chaikin, et al.
Urology|December 23, 2008
Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?M J Resnick, D J Canter, T J Guzzo, et al.
Pageof 12